Viiv Healthcare

This large, late-stage study is testing if switching from daily HIV pills to a combination of two long-acting drugs given as a monthly injection can keep the virus under control. It involved over 600 adults whose HIV was already well-managed on daily medication. The main goal is …

This study tested if switching from daily HIV pills to a monthly injection of two drugs (cabotegravir and rilpivirine) keeps the virus under control just as well. It involved 618 adults whose HIV was already suppressed on their current medication. The goal was to see if the injec…

This study is testing two different ways to control HIV in adults who have never taken HIV medication before. Everyone starts with a daily pill. Once the virus is under control, participants can choose to either stay on the pills or switch to injections they receive every two mon…

This early-stage study is testing the safety and how the body processes a new antibody called VH4527079 in healthy adults and people living with HIV. Researchers are giving single doses by injection or IV to healthy volunteers, and multiple IV doses to a small group of people wit…

This study is testing if new long-acting injections can keep HIV under control as effectively as standard daily pills. It involves adults whose HIV is already well-managed with medication. Researchers are comparing the new injection regimen, given every few months, to participant…

This early-stage study is testing the safety of new long-acting HIV drugs called capsid inhibitors in healthy volunteers. Researchers will give single injections to 85 participants and carefully monitor for side effects, particularly at the injection site. The main goal is to und…

This study is testing if switching to a simpler, two-drug HIV pill works as well as a three-drug pill for keeping the virus suppressed. It involves 205 people living with HIV who are 50 or older and have had their virus under control for at least a year. The main goal is to see i…

This study compares two daily pill regimens for adults with HIV who are starting treatment for the first time. It tests whether a simpler two-drug combination works as well as a standard three-drug combination at keeping the virus under control. Researchers will also check for si…

This early-stage study aims to understand how well healthy adults without HIV tolerate two different long-acting injection methods for HIV prevention. Researchers will give 65 participants injections in the muscle or under the skin and closely monitor any reactions at the injecti…

This study is testing a new, longer-lasting version of an injectable HIV prevention medicine. It aims to see if getting a shot every four months keeps enough medicine in the body to block HIV infection, and checks how safe and tolerable it is. The study includes 229 adolescents a…